Laura S. Mertens
A5009116808- Bladder and Urothelial Cancer Treatments
- Urinary and Genital Oncology Studies
- Urological Disorders and Treatments
- Prostate Cancer Diagnosis and Treatment
- Esophageal Cancer Research and Treatment
- Inflammatory Biomarkers in Disease Prognosis
- Urinary Bladder and Prostate Research
- Colorectal Cancer Screening and Detection
- Cancer Immunotherapy and Biomarkers
- Immune cells in cancer
- Renal cell carcinoma treatment
- Fibroblast Growth Factor Research
- Urinary Tract Infections Management
- Cancer Diagnosis and Treatment
- Multiple and Secondary Primary Cancers
- Prostate Cancer Treatment and Research
- Colorectal Cancer Surgical Treatments
- Infectious Disease Case Reports and Treatments
- Intraperitoneal and Appendiceal Malignancies
- Nanoplatforms for cancer theranostics
- Lung Cancer Treatments and Mutations
- Urologic and reproductive health conditions
- Tissue Engineering and Regenerative Medicine
- Medical Imaging Techniques and Applications
- Epigenetics and DNA Methylation
The Netherlands Cancer Institute
2016-2025
Innsbruck Medical University
2024
Istituto Oncologico Veneto
2024
Spaarne Ziekenhuis
2020
Spaarne Gasthuis
2020
Amsterdam UMC Location Vrije Universiteit Amsterdam
2017-2019
Laurens
2018
National Institute of Standards and Technology
2018
University of Liège
2014
Oncode Institute
2014
To evaluate variant histologies (VHs) for disease-specific survival (DSS) in patients with invasive urothelial bladder cancer (BCa) undergoing radical cystectomy (RC).We analysed a multi-institutional cohort of 1082 treated upfront RC cT1-4aN0M0 BCa at eight centres. Univariable and multivariable Cox' regression analyses were used to assess the effect different VHs on DSS overall three stage-based analyses. The stages defined as 'organ-confined' (≤pT2N0), 'locally advanced' (pT3-4N0)...
Objective To evaluate the clinical impact of 18 F ‐fluorodeoxyglucose ( FDG )‐positron‐emission tomography/computed tomography PET / CT ) scanning, compared with conventional staging contrast‐enhanced imaging CECT ). Patients and Methods The FDG‐PET results 96 consecutive patients bladder cancer were analysed. included in this study underwent standard chest abdomen/pelvis <4 weeks before . Based on original reports recorded tumour stage after imaging, preferred treatment strategies...
Little is known regarding functional outcomes after robot-assisted radical cystectomy (RARC) and intracorporeal neobladder (ICNB) reconstruction. To report on urinary continence (UC) erectile function (EF) at 12 mo RARC ICNB reconstruction investigate predictors of these outcomes. We used data from a multi-institutional database patients who underwent for bladder cancer. The cystoprostatectomy sensu stricto followed the conventional steps. was performed physician's discretion according to...
Background and objectiveIntermediate-risk (IR) non–muscle-invasive bladder cancer (NMIBC) encompasses a broad spectrum of disease, with heterogeneous outcomes in terms disease recurrence progression. The International Bladder Cancer Group (IBCG) recently proposed an updated scoring model for IR substratification that is based on five key risk factors. Our aim was to provide clinical validation the IBCG system NMIBC.MethodsThis international multicenter retrospective study. Patients diagnosed...
Ta grade 3 (G3) non–muscle-invasive bladder cancer (NMIBC) is a relatively rare diagnosis with an ambiguous character owing to the presence of aggressive G3 component together lower malignant potential component. The European Association Urology (EAU) NMIBC guidelines recently changed risk stratification for from high intermediate, high, or very risk. However, prognostic studies on carcinomas are limited and inconclusive. To evaluate value categorizing compared G2 T1 carcinomas. Individual...